Related Experiment Videos
[BCG immunotherapy in malignant lymphogranuloma]
Z Dientsbier1, V Foltýnová, Z Hermanská
1Ustav biofyziky a nukleární medicíny 1. lékarské fakulty Univerzity Karlovy, Praha.
Sbornik Lekarsky
|May 1, 1991
Summary
Bacillus Calmette-Guérin (BCG) immunotherapy did not significantly improve remission duration or survival rates in adult Hodgkin
Area of Science:
- Oncology
- Immunology
- Clinical Trials
Background:
- Hodgkin's disease is a cancer of the lymphatic system.
- Non-specific immunotherapies are explored to improve treatment outcomes.
Purpose of the Study:
- To evaluate the efficacy of Bacillus Calmette-Guérin (BCG) immunotherapy as an adjunct treatment for adult Hodgkin's disease.
- To assess the impact of BCG immunotherapy on remission duration, survival rates, and work capacity.
Main Methods:
- A multicentre, randomized, and stratified investigation.
- 112 patients received supplementary BCG treatment, compared with 114 patients in a control group.
- Prospective study protocol and Cox' regression analysis were utilized.
Main Results:
- Mean remission duration was 94 months for BCG-vaccinated patients versus 74 months for controls (not statistically significant).
- Five-year survival was 93% (vaccinated) vs. 91% (control); 10-year survival was 88% vs. 85%.
- No significant differences observed in work capacity or prognostic favorability via Cox' regression analysis.
Conclusions:
- Supplementary BCG immunotherapy did not demonstrate a statistically significant benefit in improving remission duration or survival for adult Hodgkin's disease patients.
- BCG immunotherapy was not identified as a favorable prognostic factor in this patient cohort.